Insmed to Host Second Quarter 2017 Financial Results Conference Call on Thursday, August 3, 2017
July 27 2017 - 8:00AM
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical
company focused on the unmet needs of patients with rare diseases,
today announced that it will release its second quarter 2017
financial results on Thursday, August 3, 2017.
Insmed management will host a conference call for investors
beginning at 8:30 a.m. ET on Thursday, August 3, 2017 to discuss
the financial results and provide a business update.
Shareholders and other interested parties may participate in the
conference call by dialing (844) 707-0669 (domestic) or (703)
639-1223 (international) and referencing conference ID number
53207980. The call will also be webcast live on the internet on the
company's website at www.insmed.com.
A replay of the conference call will be accessible approximately
two hours after its completion through August 17, 2017 by dialing
(855) 859-2056 (domestic) or (404) 537-3406 (international) and
referencing conference ID number 53207980. A webcast of the call
will also be archived for 90 days under the Investor Relations
section of the company's website at www.insmed.com.
About Insmed
Insmed Incorporated is a global biopharmaceutical company
focused on the unmet needs of patients with rare diseases. The
Company is advancing a global phase 3 clinical study of amikacin
liposome inhalation suspension (ALIS) for adult patients with
treatment refractory NTM lung disease caused by MAC, a rare and
often chronic infection that is capable of causing irreversible
lung damage and can be fatal. There are currently no approved
inhaled products specifically indicated for the treatment of
refractory NTM lung infections caused by MAC in the United
States or European Union (EU). Insmed's
earlier-stage clinical pipeline includes INS1007, a novel oral
reversible inhibitor of DPP1 with therapeutic potential in non-CF
bronchiectasis, and INS1009, an inhaled nanoparticle
formulation of a treprostinil prodrug that may offer a
differentiated product profile for rare pulmonary disorders,
including pulmonary arterial hypertension (PAH). For more
information, visit www.insmed.com.
"Insmed" is the Company's trademark. All other trademarks, trade
names or service marks appearing in this press release are the
property of their respective owners.
Investor Contact:
Blaine Davis
VP, Head of Investor Relations
908-947-2841
Blaine.Davis@insmed.com
Insmed (NASDAQ:INSM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Insmed (NASDAQ:INSM)
Historical Stock Chart
From Sep 2023 to Sep 2024